Clinical Trials
83 trialsNCT04931823 2026-04-03
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
Phase 1 Terminated
NCT02744287 2026-02-23
Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors
Regeneron Pharmaceuticals
Phase 1 Terminated
NCT05037500 2025-11-12
Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Roswell Park Cancer Institute
Phase 1 Terminated
NCT05252390 2025-11-06
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Nuvation Bio Inc.
Phase 1 Terminated
NCT03792841 2025-10-16
Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC
Amgen
Phase 1 Terminated
NCT05276492 2025-10-03
Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.
University of Chicago
Phase 1 Terminated
NCT05733351 2025-09-15
Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer
Emory University
Phase 1 Terminated
NCT05605522 2025-08-24
A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours
3B Pharmaceuticals GmbH
Phase 1 Terminated
NCT05369000 2025-08-01
Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer
Lava Therapeutics
Phase 1 Terminated
NCT04740034 2025-06-17
A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma
Amgen
Phase 1 Terminated
NCT04927663 2025-05-20
11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression
University of California, San Francisco
Phase 1 Terminated
NCT03300505 2025-05-13
ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 1 Terminated
NCT03490838 2025-05-13
PROter
Advanced Accelerator Applications
Phase 1 Terminated
NCT01341288 2025-05-02
EUCLIDIAN
Thomas Jefferson University
Phase 1 Terminated
NCT04586270 2025-03-13
A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer
Taiho Oncology, Inc.
Phase 1 Terminated
NCT04421222 2025-02-28
EPI-7386
ESSA Pharmaceuticals
Phase 1 Terminated
NCT04249947 2025-02-17
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
Poseida Therapeutics, Inc.
Phase 1 Terminated
NCT05295927 2025-02-03
A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)
Janssen Research & Development, LLC
Phase 1 Terminated
NCT04291664 2024-10-17
PK and Dose Escalation and Expansion Study of DST-2970
DisperSol Technologies, LLC
Phase 1 Terminated
NCT05156905 2024-10-09
Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer
University of California, San Diego
Phase 1 Terminated
NCT05679388 2024-09-19
A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients
University of Chicago
Phase 1 Terminated
NCT00848601 2024-08-02
Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma
Astex Pharmaceuticals, Inc.
Phase 1 Terminated
NCT03685591 2024-06-26
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT03066154 2024-06-03
DOP
The Netherlands Cancer Institute
Phase 1 Terminated
NCT04633148 2024-04-23
Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker
AvenCell Therapeutics, Inc.
Phase 1 Terminated
NCT04677855 2024-04-10
Study of PCUR-101 in Combination With ADT in Patients With mCRPC
Pellficure Pharmaceuticals, Inc
Phase 1 Terminated
NCT04586335 2024-03-21
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
Haihe Biopharma Co., Ltd.
Phase 1 Terminated
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT02995330 2024-02-13
Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated
NCT04528199 2024-01-16
[18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated
NCT04033328 2023-12-15
Study of ORIC-101 in Combination With Enzalutamide
ORIC Pharmaceuticals
Phase 1 Terminated
NCT03861403 2023-11-30
A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
Leap Therapeutics, Inc.
Phase 1 Terminated
NCT02616185 2023-11-02
A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)
Pfizer
Phase 1 Terminated
NCT03619655 2023-10-31
Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated
NCT02809690 2023-09-07
18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer
University of Southern California
Phase 1 Terminated
NCT04227275 2023-08-21
A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer
Tceleron Therapeutics, Inc.
Phase 1 Terminated
NCT04575766 2023-08-09
A Study of FT-7051 in Men With MCRPC
Novo Nordisk A/S
Phase 1 Terminated
NCT04541225 2023-07-14
Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
Nuvation Bio Inc.
Phase 1 Terminated
NCT03927573 2023-07-10
Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker
AvenCell Therapeutics, Inc.
Phase 1 Terminated
NCT00788307 2023-04-18
Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to External-Beam Radiation Therapy
Mayo Clinic
Phase 1 Terminated
NCT02844647 2023-03-28
Hyperpolarized Carbon-13 Imaging of Metastatic Prostate Cancer
Sunnybrook Health Sciences Centre
Phase 1 Terminated
NCT01174199 2022-10-03
Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer
Roswell Park Cancer Institute
Phase 1 Terminated
NCT04279561 2022-09-21
Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer
Jonsson Comprehensive Cancer Center
Phase 1 Terminated
NCT02628535 2022-02-08
Safety Study of MGD009 in B7-H3-expressing Tumors
MacroGenics
Phase 1 Terminated
NCT02767921 2021-11-24
sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer
University of Southern California
Phase 1 Terminated
NCT02963051 2021-09-16
A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer
Duke University
Phase 1 Terminated
NCT03478904 2021-05-10
Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT00493766 2020-12-19
Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone
Novartis
Phase 1 Terminated
NCT02911467 2020-07-24
MR
University of California, San Francisco
Phase 1 Terminated
NCT03043989 2020-02-17
Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated